Zelgen Biopharma's First-in-Class Trispecific Antibody ZG006 Combination Therapy Receives IND Approval for Extensive-Stage Small Cell Lung Cancer

Apr 09, 2026 17:31 CST Updated 17:31

Zelgen

Innovative Drug Research and Development, Manufacturer

Hansoh Pharma

Pharmaceutical Research, Production, and Sales

On April 9, Suzhou Zelgen Biopharmaceuticals Co., Ltd. (Stock Code: 688266) announced that the company has recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration.ZG006 for Injection in Combination with HS-20093 for Injection, with or without Adebrelimab Injection, for the Treatment of Extensive-Stage Small Cell Lung CancerThe clinical trial has been officially approved. This is another key clinical layout breakthrough for this world's first First-in-Class trispecific antibody in the field of refractory lung cancer.

1. Full Review of Core Approval Information

The clinical trial protocol approved this time is an innovative combination therapy for extensive-stage small cell lung cancer. The core drug and protocol information are as follows:

1.Core Primary Drug: ZG006 for Injection, a powder injection independently developed by Zelgen, is available in specifications of 1mg/vial and 5mg/vial, serving as the core cornerstone drug in this combination therapy;

2.Combination Therapy：HS-20093 for Injection (a B7-H3-targeted ADC developed by Hansoh Pharma), Adebrelimab Injection (PD-L1 inhibitor);

3. Applicable PopulationPatients with extensive-stage small cell lung cancer, one of the most malignant subtypes of lung cancer with the poorest prognosis, have long had unmet clinical treatment needs.

4. Approval ProgressThe application was accepted on January 22, 2026. After review by the National Medical Products Administration, it met the relevant requirements for drug registration, and clinical trials were approved to proceed.

2. Core Highlights Breakdown: World's First-in-Class Triple Antibody, Targeting Key Small Cell Lung Cancer Targets

The core protagonist of the approved plan this time, ZG006, was developed by Zelgen through its proprietary dual/multi-specific antibody R&D platform.Trispecific Antibody Drug, which is also the biggest highlight of this clinical approval. Its core value has long been recognized by regulatory agencies both in China and internationally:

World's First Molecular Form: ZG006 is a trispecific T-cell engager targeting two distinct DLL3 epitopes and CD3, and is alsoThe world's first trispecific antibody targeting DLL3 (DLL3/DLL3/CD3), a pure First-in-Class molecule with the potential to become a Best-in-Class molecule;
Heavyweight Qualifications: The product has successively obtained clinical trial approvals from China's NMPA and the U.S. FDA, and has been included by the CDE.Breakthrough Therapy Drug`, while also receiving the U.S. FDA's`Orphan Drug Designation, the R&D value has been recognized by regulatory authorities worldwide;
Impressive Clinical DataAt the 2025 ESMO Asia Congress, Zelgen has released clinical research data on ZG006, demonstrating its therapeutic potential in DLL3-positive solid tumors, particularly small cell lung cancer.

DLL3 is a core target highly expressed in small cell lung cancer (SCLC) and plays a crucial role in tumorigenesis and development, making it a popular research direction in the field of SCLC treatment. ZG006, with its design of dual-epitope targeting DLL3 and simultaneous CD3-mediated T-cell activation, can more precisely and efficiently activate the immune system to kill tumor cells, demonstrating stronger anti-tumor activity compared to traditional monoclonal antibodies.

III. Innovative Combination Therapy: Mechanism Complementarity, Directly Addressing the Pain Points in Extensive-Stage Small Cell Lung Cancer Treatment

Extensive-Stage Small Cell Lung Cancer: A Recognized "Tough Challenge" in the Field of Lung Cancer

The core advantage of the three-drug/two-drug combination regimen approved this time lies inMechanisms Complement Each Other, Synergistically Enhance Efficacy, precisely targeting the challenges of drug resistance and treatment in small cell lung cancer:

1. ZG006 (DLL3 Trispecific Antibody):By targeting DLL3 with dual epitopes, it precisely locks onto tumor cells while activating T cells, achieving specific immune killing of tumor cells.

2. HS-20093 (B7-H3 Targeting ADC):Hansoh Pharma has developed a novel antibody-drug conjugate (ADC) composed of a fully human anti-B7-H3 monoclonal antibody linked to a topoisomerase inhibitor payload. B7-H3 is highly expressed in small cell lung cancer and can deliver chemotherapy drugs precisely through the ADC, directly killing tumor cells and synergizing with immunotherapy.

3. Adebrelimab Injection (PD-L1 Inhibitor):By blocking the PD-1/PD-L1 pathway, the tumor immune microenvironment is improved, further amplifying the anti-tumor effects of T cells and enhancing the therapeutic efficacy of combination therapies.

From single-target drugs to a full-dimensional combination of "trispecific antibodies + ADC + immunotherapy," this regimen covers three major anti-tumor mechanisms: immune killing, precise chemotherapy, and microenvironment modulation. It is expected to break through the current treatment bottleneck for small cell lung cancer and bring new therapeutic options to patients with drug resistance.

4. Industry Significance: From Molecular Innovation to Breakthroughs in Combination Therapies, China-Produced Innovative Drugs Tackle Difficult-to-Treat Cancers

This clinical approval is not only an important milestone in Zelgen's R&D pipeline but also another profound breakthrough for Chinese-produced innovative drugs in the field of refractory cancers.

For Zelgen, this approval further expands the clinical application scenarios of ZG006, synergizing with the company's existing pipeline and consolidating its first-mover advantage in the multispecific antibody field. At the same time, conducting joint clinical trials with innovative drug products from Hansoh Pharma and Hengrui Medicine has pioneered a new model of collaborative R&D for innovative pipelines among pharmaceutical companies in China, achieving complementary advantages and accelerating the R&D process.

For the industry, in the past, domestic innovation drug research and development in China mainly focused on follow-up innovations targeting a single target. However, today, companies represented by Zelgen have achieved full-chain breakthroughs from "First-in-Class molecular source innovation" to "clinical exploration of innovative combination therapies." In response to small cell lung cancer, a globally difficult-to-treat tumor, Chinese pharmaceutical companies have begun to take the lead in global research and development, truly focusing on unmet clinical needs to develop original Chinese treatments that are world-leading.

5. Compliance Risk Notice

New drug research and development hasHigh technology, high investment, high risk, long cycleThe characteristic of this approval is that it is only for the clinical trial application. Before the drug can be approved for marketing, it still needs to complete several key steps, including Phase I-III clinical trials, marketing registration submission, on-site production inspection, and drug lot release. The results of the clinical trials, the progress of the review and approval process, and whether the drug will ultimately be approved for marketing all carry uncertainties.

The announcement also clarified that the approval of this clinical trial will not have a significant impact on the company's recent performance. We remind industry practitioners and investors to view the R&D progress rationally, make decisions prudently, and be mindful of investment risks.

Notes

After years of reporting on the pharmaceutical industry, small cell lung cancer has always been a field we have kept a close eye on. After countless patients develop resistance to first-line treatments, they fall into the dilemma of having no available drugs, which is the most pressing unmet need in clinical practice.

From relying on imported chemotherapy drugs in the past, to domestically produced PD-L1 inhibitors achieving frontline breakthroughs, and now to the approval for clinical use of the world's first innovative solution combining a tri-specific antibody with ADC and immunotherapy, we have personally witnessed the complete transformation of China-produced innovative drugs in this difficult-to-treat cancer field—from "catching up" to "leading the way."

The approval of Zelgen's ZG006 combination regimen is just the beginning. We will continue to track patient enrollment, data readouts, and subsequent development progress in this clinical trial. We look forward to this China-originated First-in-Class drug bringing new hope for survival to patients with extensive-stage small cell lung cancer as soon as possible.

? Interactive Topic:What do you think about the exploration of combination therapies for refractory tumors by domestically produced innovative drugs in China? Feel free to leave comments and exchange ideas in the comment section.

Scan the WeChat QR code to add.Medicine Space-TimeEditor
Please indicate: Name + Research Direction!